The Research Roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Most patients with esophageal adenocarcinoma (EAC) present with de novo tumors. Although this could be due to inadequate screening strategies, the precise reason for this observation is not clear. Mayo Clinic researchers compared survival of patients with prevalent EAC with and without synchronous Barrett esophagus (BE) with intestinal metaplasia (IM) at the time of EAC diagnosis. Clinical data were studied using Cox proportional hazards regression to evaluate the effect of synchronous BE-IM on EAC survival independent of age, sex, TNM stage, and tumor location. Researchers analyzed data from a cohort of patients with EAC from the Mayo Clinic and a multicenter cohort from the United Kingdom. Two types of EAC can be characterized based on the presence or absence of BE. These findings could increase the understanding of the etiology of EAC and be used in management and prognosis of patients. The study was published in Gastroenterology.